|

MK-7075 (miransertib) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • National Human Genome Research Institute (NHGRI)1

Indications

  • Proteus Syndrome1
  • Cancer1

Bethesda, Maryland1 trial

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.